Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Sage Therapeutics, Inc.

Sage Therapeutics is a biopharmaceutical company focused on developing medicines for brain health disorders, particularly postpartum depression.

Metric
Company Name	Sage Therapeutics, Inc.
Symbol	SAGE
MSH ID	COM:SAGERX
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage	Post-IPO
Employee Count	487
Website	sagerx.com
LinkedIn
Founders

Metric
Market Cap	663.81M
Enterprise Value
Monthly Web Traffic	14.61K
Web Traffic Growth	0.68
Valuation
Raised Capital	650M

Metric
Revenue	86.45M
Revenue (LTM)
Revenue (NTM)
Gross Profit	84.30M
EBITDA	-511.68M
Operating Income	-579.85M
Net Income	-541.49M
EPS	-9.05
Diluted EPS	-9.05
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.98
Operating Profit Margin	-4.96
EBITDA Margin	-5.92
Net Profit Margin	-4.58
Return on Equity	-0.57
Return on Assets	-0.60
Return on Capital Employed	-0.73

COM:SAGERX

Sage Therapeutics

Last Close

4.85

22/11 21:00

Market Cap

663.81M

Beta: -

Volume Today

871.04K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.29
P/B Ratio	1.78
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	13.54
EV Multiple	-1.18

Metric
Days Sales Outstanding	724.05
Days Payables Outstanding	2.74K
Days Inventory Outstanding	225.08
Operating Cycle	575.53
Cash Conversion Cycle	-665.81
Asset Turnover	0.14

Metric
Operating Cash Flow	-540.59M
Free Cash Flow	-541.14M
Cash Flow to Debt	-104.66
Operating Cash Flow/Sales	-3.02
Free Cash Flow Yield	-0.38

Metric
Cash & Equivalents	70.99M
Accounts Receivable	-69.35M
Inventory	1.33M
Goodwill
Debt to Capitalization	0.01
Debt to Assets	0.01
Current Ratio	7.02
Quick Ratio	12.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	6.67
R&D to Revenue	33.59
SG&A to Revenue	25.26